ReviewFrontiers in immunology2026
Dual roles of immunosenescence in cancer immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence of tumor-infiltrating immune cells represents a hallmark of tumorigenesis, characterized by functional decline and severely compromised anti-tumor immunity. A growing body of evidence indicates that immunosenescence is not only a significant biological phenomenon within the tumor microenvironment (TME) but also serves as a therapeutic target with dual regulatory potential. Previous reviews have thoroughly examined the biomarkers associated with immunosenescence and its overarching impact on aging and disease. Nonetheless, comprehensive analyses of its specific and dual roles in cancer immunotherapy outcomes are still lacking. Consequently, a novel paradigm has been proposed for targeting immunosenescence: modulating the function of senescent immune cells may offer innovative cancer treatment strategies. This review synthesizes the bidirectional relationship between immune cell senescence and tumor progression, systematically examining the interactions between senescent immune cells and tumor advancement, and underscores the key molecular mechanisms driving immune senescence within the TME. By elucidating the characteristics and functions of immune cell senescence in tumor development and immune evasion, we aim to uncover new therapeutic perspectives and highlight potential targets for cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.